Table 2.
Benign IP | IP with carcinoma |
Significance | |
---|---|---|---|
p16 + (%) | 85/133 (64%) | 3/21 (14%) | p<0.001 |
EGFR+ (%) | 68/135 (50%) | 15/21 (71%) | NS |
P53+ (%) | 45/135 (30%) | 13/21 (62%) | p<0.001 |
Cyclin D1+ (%) | 104/136 (76%) | 16/21 (76%) | NS |
Benign IP | IP with carcinoma |
Significance | |
---|---|---|---|
p16 + (%) | 85/133 (64%) | 3/21 (14%) | p<0.001 |
EGFR+ (%) | 68/135 (50%) | 15/21 (71%) | NS |
P53+ (%) | 45/135 (30%) | 13/21 (62%) | p<0.001 |
Cyclin D1+ (%) | 104/136 (76%) | 16/21 (76%) | NS |